Studies have shown that cancer cells increase [103] uptake by upregulating plasma glutamine transporters ASCT 2/SLC1A5 (Alanine‐Serine‐Cysteine Transporter/Solute Carrier Family 1 Member 5, ASCT2/SLC1A5) and SN2/SLC38A5 (Nucleophilic Substitution/Solute Carrier Family 38 Member 5, SN2/SLC38A5), which are then converted to glutamate [104] in mitochondria by two forms of glutaminase (Kidney‐type glutamine amidase, GLS 1 and Liver‐type glutaminase, GLS 2). This evidence concerns the gene SLC38A5 and cancer.